T
Takao Shishido
Publications - 42
Citations - 1823
Takao Shishido is an academic researcher. The author has contributed to research in topics: Virus & Influenza A virus. The author has an hindex of 13, co-authored 32 publications receiving 1224 citations.
Papers
More filters
Journal ArticleDOI
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
Frederick G. Hayden,Sugaya N,Hirotsu N,Nelson Lee,de Jong,Aeron C. Hurt,Ishida T,Sekino H,Yamada K,Simon Portsmouth,Keiko Kawaguchi,Takao Shishido,Arai M,Kenji Tsuchiya,Takeki Uehara,Akira Watanabe +15 more
TL;DR: Single‐dose baloxavir was without evident safety concerns, was superior to placebo in alleviating influenza symptoms, and was superiorto both oseltamivir and placebo in reducing the viral load 1 day after initiation of the trial regimen in patients with uncomplicated influenza.
Journal ArticleDOI
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.
Shinya Omoto,Valentina Speranzini,Takashi Hashimoto,Takeshi Noshi,Hiroto Yamaguchi,Makoto Kawai,Keiko Kawaguchi,Takeki Uehara,Takao Shishido,Akira Naito,Stephen Cusack +10 more
TL;DR: It is found that the PA I38T substitution is a major pathway for reduced susceptibility to BXA, with 30- to 50-fold and 7-fold EC50 changes in A and B viruses, respectively.
Journal ArticleDOI
In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
Takeshi Noshi,Mitsutaka Kitano,Keiichi Taniguchi,Atsuko Yamamoto,Shinya Omoto,Keiko Baba,Takashi Hashimoto,Kayo Ishida,Yukihiro Kushima,Kazunari Hattori,Makoto Kawai,Ryu Yoshida,Masanori Kobayashi,Tomokazu Yoshinaga,Akihiko Sato,Masatoshi Okamatsu,Yoshihiro Sakoda,Hiroshi Kida,Takao Shishido,Akira Naito +19 more
TL;DR: The results reveal the in vitro characteristics of BXA and support clinical use of BXM to treat influenza and support in vitro characterization of a novel CEN inhibitor, baloxavir acid (BXA), the active form of baloxvir marboxil.
Journal ArticleDOI
Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
Takeki Uehara,Frederick G. Hayden,Keiko Kawaguchi,Shinya Omoto,Aeron C. Hurt,Menno D. de Jong,Nobuo Hirotsu,Norio Sugaya,Nelson Lee,Keiko Baba,Takao Shishido,Kenji Tsuchiya,Simon Portsmouth,Hiroshi Kida +13 more
TL;DR: The emergence of viruses with PA/I38X substitutions following baloxavir treatment was associated with transient rises in infectious virus titers, prolongation of virus detectability, initial delay in symptom alleviation, and uncommonly with symptom rebound.
Journal ArticleDOI
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial
Michael G. Ison,Simon Portsmouth,Yuki Yoshida,Takao Shishido,Melissa Mitchener,Kenji Tsuchiya,Takeki Uehara,Frederick G. Hayden +7 more
TL;DR: The primary endpoint was time to improvement of influenza symptoms (TTIIS) in the modified intention-to-treat population, which included all patients who received at least one dose of study drug and had RT-PCR-confirmed influenza virus infection.